laminin subunit alpha 3
Zuletzt aktualisiert 12. Apr 2023
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Der LAMA3 gene provides instructions for making one part (subunit) of a protein called laminin 332 (formerly known as laminin 5). This protein is made up of three subunits, called alpha, beta, and gamma. The LAMA3 gene carries instructions for the alpha subunit; the beta and gamma subunits are produced from other genes. Three versions of the alpha subunit, called alpha-3a, alpha-3b1, and alpha-3b2, are produced from the LAMA3 gene.
Normal function
Der LAMA3 gene provides instructions for making one part (subunit) of a protein called laminin 332 (formerly known as laminin 5). This protein is made up of three subunits, called alpha, beta, and gamma. The LAMA3 gene carries instructions for the alpha subunit; the beta and gamma subunits are produced from other genes. Three versions of the alpha subunit, called alpha-3a, alpha-3b1, and alpha-3b2, are produced from the LAMA3 gene.
Laminins are a group of proteins that regulate cell growth, cell movement (motility), and the attachment of cells to one another (adhesion). They are also involved in the formation and organisation of basement membranes, which are thin, sheet-like structures that separate and support cells in many tissues. Laminin 332 has a particularly important role in the basement membrane that underlies the top layer of skin (the epidermis). This membrane gives strength and resiliency to the skin and creates an additional barrier between the body and its surrounding environment. Laminin 332 is a major component of fibers called anchoring filaments, which connect the two layers of the basement membrane and help hold the skin together.
Studies suggest that laminin 332 also has several other functions. This protein appears to be important in the formation of early wound-healing tissues. Additionally, researchers have proposed roles for laminin 332 in the clear outer covering of the eye (the cornea) and in the development of tooth enamel.
The alpha subunit produced from the LAMA3 gene is also part of two other laminin proteins, laminin 311 and laminin 321. These laminins also appear to provide strength to the skin, although they do not play as big a role as laminin 332. In addition, laminin 311 is involved in cell signaling in the lungs and other tissues.
Conditions referring to this gene or chromosome
Other names
BM600
BM600 150kD subunit
BM600-150kDa
E170
epiligrin
epiligrin 170 kda subunit
epiligrin alpha 3 subunit
kalinin 165kD subunit
kalinin-165kDa
LAM5, alpha-3 subunit
LAMA3_HUMAN
lama3a
laminin 5, alpha-3 subunit
laminin A3
laminin alpha 3
laminin alpha 3 subunit
laminin, alpha 3
laminin, alpha-3
laminin-5 alpha 3 chain
LAMNA
LOCS
nicein 150kD subunit
nicein-150kDa
Related patient information and medicines

Patient information leaflet
Restless-Legs-Syndrom
Sekundär verursacht Symptome von secondary RLS can develop as a. For example: Pregnancy. About 1 in 5 pregnant women develop restless legs syndrome in pregnancy (especially in the later part of pregnancy). Symptoms often go away after a woman has given birth, but women who have RLS during pregnancy are four times as likely to develop RLS later in life.

Patient information leaflet
Hodenkrebs
Hodenkrebs is a Krebs that arises from a testicle (testis). Around half of all cases occur in men aged under 35 but testicular cancer rarely occurs before puberty. Another useful test i... The tumour markers commonly tested for are Alpha-Fetoprotein (AFP), beta human chorionic gonadotrophin (beta-hCG), lactic dehydrogenase (LDH) and.

Patient information leaflet
Polymorphe Lichtdermatose
Polymorphic light eruption is a skin rash that can happen when you go out in the sun. Polymorphic light eruption symptoms Polymorphic light eruption (PMLE) is a rash which comes on after being in strong sunlight. It looks like reddened skin with raised red spots or small blisters. It is generally itchy and uncomfortable. It can feel sore or.

Patient information leaflet
Psoriasis-Arthritis
The National Institute for Health and Care Excellence (NICE) guidelines advise that etanercept, infliximab, adalimumab or golimumab should be offered as an option for treating adults with psoriatic arthritis when: The person has arthritis with three or more tender joints and three or more swollen joints; and When at least two other DMARDs, given.

Patient information leaflet
Leberversagen
This is called chronische Leber disease. See the separate leaflet called Cirrhosis for further information. Liver failure can also develop rapidly over just a few days (acute liver failure). There are many causes of acute liver failure. These include paracetamol poisoning, infections (for example, hepatitis B or hepatitis C), acute fatty liver of.

Patient information leaflet
Biologische Arzneimittel gegen rheumatoide Arthritis
Biologische Medikamente are a newer type of medicine, used to ease the symptoms of rheumatoide Arthritis and reduce the damaging effect of the disease on the joints. They are usually prescribed when you have tried older medicines called disease-modifying antirheumatic drugs (DMARDs) and these have not worked so well. If a biological medicine is going.
Weiterführende Lektüre und Referenzen
- laminin subunit alpha 3; MedlinePlus, National Library of Medicine.
- Aumailley M, Bruckner-Tuderman L, Carter WG, Deutzmann R, Edgar D, Ekblom P, Engel J, Engvall E, Hohenester E, Jones JC, Kleinman HK, Marinkovich MP, Martin GR, Mayer U, Meneguzzi G, Miner JH, Miyazaki K, Patarroyo M, Paulsson M, Quaranta V, Sanes JR, Sasaki T, Sekiguchi K, Sorokin LM, Talts JF, Tryggvason K, Uitto J, Virtanen I, von der Mark K, Wewer UM, Yamada Y, Yurchenco PD. A simplified laminin nomenclature. Matrix Biol. 2005 Aug;24(5):326-32. doi: 10.1016/j.matbio.2005.05.006.
- Barzegar M, Mozafari N, Kariminejad A, Asadikani Z, Ozoemena L, McGrath JA. A new homozygous nonsense mutation in LAMA3A underlying laryngo-onycho-cutaneous syndrome. Br J Dermatol. 2013 Dec;169(6):1353-6. doi: 10.1111/bjd.12522.
- Hamill KJ, McLean WH. The alpha-3 polypeptide chain of laminin 5: insight into wound healing responses from the study of genodermatoses. Clin Exp Dermatol. 2005 Jul;30(4):398-404. doi: 10.1111/j.1365-2230.2005.01842.x.
- Hamill KJ, Paller AS, Jones JC. Adhesion and migration, the diverse functions of the laminin alpha3 subunit. Dermatol Clin. 2010 Jan;28(1):79-87. doi: 10.1016/j.det.2009.10.009.
- Hartwig B, Borm B, Schneider H, Arin MJ, Kirfel G, Herzog V. Laminin-5-deficient human keratinocytes: defective adhesion results in a saltatory and inefficient mode of migration. Exp Cell Res. 2007 May 1;313(8):1575-87. doi: 10.1016/j.yexcr.2007.02.003. Epub 2007 Feb 9.
- Kim CC, Liang MG, Pfendner E, Kimonis VE. What syndrome is this? Laryngo-onycho-cutaneous syndrome. Pediatr Dermatol. 2007 May-Jun;24(3):306-8. doi: 10.1111/j.1525-1470.2007.00408.x. No abstract available.
- McLean WH, Irvine AD, Hamill KJ, Whittock NV, Coleman-Campbell CM, Mellerio JE, Ashton GS, Dopping-Hepenstal PJ, Eady RA, Jamil T, Phillips R, Shabbir SG, Haroon TS, Khurshid K, Moore JE, Page B, Darling J, Atherton DJ, Van Steensel MA, Munro CS, Smith FJ, McGrath JA. An unusual N-terminal deletion of the laminin alpha3a isoform leads to the chronic granulation tissue disorder laryngo-onycho-cutaneous syndrome. Hum Mol Genet. 2003 Sep 15;12(18):2395-409. doi: 10.1093/hmg/ddg234. Epub 2003 Jul 15.
- Nakano A, Chao SC, Pulkkinen L, Murrell D, Bruckner-Tuderman L, Pfendner E, Uitto J. Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs. non-Herlitz phenotypes. Hum Genet. 2002 Jan;110(1):41-51. doi: 10.1007/s00439-001-0630-1. Epub 2001 Nov 13.
- Schneider H, Muhle C, Pacho F. Biological function of laminin-5 and pathogenic impact of its deficiency. Eur J Cell Biol. 2007 Dec;86(11-12):701-17. doi: 10.1016/j.ejcb.2006.07.004. Epub 2006 Sep 26.
- Varki R, Sadowski S, Pfendner E, Uitto J. Epidermolysis bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants. J Med Genet. 2006 Aug;43(8):641-52. doi: 10.1136/jmg.2005.039685. Epub 2006 Feb 10.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
12. Apr 2023 | Neueste Version
1 Sept 2014 | Ursprünglich veröffentlicht
Nehmen Sie an der Diskussion teil
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.

Fragen, teilen, verbinden.
Durchsuchen Sie Diskussionen, stellen Sie Fragen und teilen Sie Erfahrungen zu Hunderten von Gesundheitsthemen.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.